Author:
Wang M,Fowler N,Wagner-Bartak N,Feng L,Romaguera J,Neelapu S S,Hagemeister F,Fanale M,Oki Y,Pro B,Shah J,Thomas S,Younes A,Hosing C,Zhang L,Newberry K J,Desai M,Cheng N,Badillo M,Bejarano M,Chen Y,Young K H,Champlin R,Kwak L,Fayad L
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference43 articles.
1. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 110: 695–708.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et alIn, 2008 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman J (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Systems, Follicular Lymphoma 4th edn IARC: Lyon, pp 220–228.
3. Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D et al. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997; 15: 1654–1663.
4. Bierman PJ . Natural history of follicular grade 3 non-Hodgkin's lymphoma. Curr Opin Oncol 2007; 19: 433–437.
5. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105–116.